Clinical Trial Update: Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) [Phase 2]

View source ↗

Summary

This clinical trial update describes the SHAMROCK study, a phase II neoadjuvant treatment using trastuzumab deruxtecan (T-DXd) followed by response-directed def…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Cancer Trials Ireland | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING